Suppr超能文献

人肝癌细胞系HepG2对人极低密度脂蛋白的结合与降解研究。

Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2.

作者信息

Dashti N, Wolfbauer G

出版信息

Biochim Biophys Acta. 1986 Feb 28;875(3):473-86. doi: 10.1016/0005-2760(86)90067-6.

Abstract

The regulation of the hepatic catabolism of normal human very-low-density lipoproteins (VLDL) was studied in human-derived hepatoma cell line HepG2. Concentration-dependent binding, uptake and degradation of 125I-labeled VLDL demonstrated that the hepatic removal of these particles proceeds through both the saturable and non-saturable processes. In the presence of excess unlabeled VLDL, the specific binding of 125-labeled VLDL accounted for 72% of the total binding. The preincubation of cells with unlabeled VLDL had little effect on the expression of receptors, but reductive methylation of VLDL particles reduced their binding capacity. Chloroquine and colchicine inhibited the degradation of 125I-labeled VLDL and increased their accumulation in the cell, indicating the involvement of lysosomes and microtubuli in this process. Receptor-mediated degradation was associated with a slight (13%) reduction in de novo sterol synthesis and had no significant effect on the cellular cholesterol esterification. Competition studies demonstrated the ability of unlabeled VLDL, low-density lipoproteins (LDL) and high-density lipoproteins (HDL) to effectively compete with 125I-labeled VLDL for binding to cells. No correlation was observed between the concentrations of apolipoproteins A-I, A-II, C-I, C-II and C-III of unlabeled lipoproteins and their inhibitory effect on 125I-labeled VLDL binding. When unlabeled VLDL, LDL and HDL were added at equal contents of either apolipoprotein B or apolipoprotein E, their inhibitory effect on the binding and uptake of 125I-labeled VLDL only correlated with apolipoprotein E. Under similar conditions, the ability of unlabeled VLDL, LDL and HDL to compete with 125I-labeled LDL for binding was a direct function of only their apolipoprotein B. These results demonstrate that in HepG2 cells, apolipoprotein E is the main recognition signal for receptor-mediated binding and degradation of VLDL particles, while apolipoprotein B functions as the sole recognition signal for the catabolism of LDL. Furthermore, the lack of any substantial regulation of beta-hydroxy-beta-methylglutaryl-CoA reductase and acyl-CoA:cholesterol acyltransferase activities subsequent to VLDL degradation, in contrast to that observed for LDL catabolism, suggests that, in HepG2 cells, the receptor-mediated removal of VLDL proceeds through processes independent of those involved in LDL catabolism.

摘要

在人源肝癌细胞系HepG2中研究了正常人极低密度脂蛋白(VLDL)的肝脏分解代谢调节。125I标记的VLDL的浓度依赖性结合、摄取和降解表明,这些颗粒的肝脏清除通过可饱和和不可饱和过程进行。在存在过量未标记VLDL的情况下,125I标记的VLDL的特异性结合占总结合的72%。用未标记的VLDL对细胞进行预孵育对受体表达影响很小,但VLDL颗粒的还原甲基化降低了它们的结合能力。氯喹和秋水仙碱抑制125I标记的VLDL的降解并增加它们在细胞中的积累,表明溶酶体和微管参与了这一过程。受体介导的降解与从头合成固醇略有减少(13%)有关,对细胞胆固醇酯化没有显著影响。竞争研究表明,未标记的VLDL、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)能够与125I标记的VLDL有效竞争结合细胞。未标记脂蛋白的载脂蛋白A-I、A-II、C-I、C-II和C-III的浓度与其对125I标记的VLDL结合的抑制作用之间未观察到相关性。当以载脂蛋白B或载脂蛋白E的等量添加未标记的VLDL、LDL和HDL时,它们对125I标记的VLDL结合和摄取的抑制作用仅与载脂蛋白E相关。在类似条件下,未标记的VLDL、LDL和HDL与125I标记的LDL竞争结合的能力仅是它们载脂蛋白B的直接函数。这些结果表明,在HepG2细胞中,载脂蛋白E是受体介导的VLDL颗粒结合和降解的主要识别信号,而载脂蛋白B是LDL分解代谢的唯一识别信号。此外,与LDL分解代谢观察到的情况相反,VLDL降解后β-羟基-β-甲基戊二酰辅酶A还原酶和酰基辅酶A:胆固醇酰基转移酶活性缺乏任何实质性调节,这表明在HepG2细胞中,受体介导的VLDL清除通过与LDL分解代谢所涉及的过程无关的过程进行。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验